[Comment] Now or later? Switching therapies in metastatic breast cancer | ClinicLens
In contemporary management of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is standard to switch therapies at tumour progression, defined by RECIST criteria in clinical trials, and by other measures (many, ironically, considered non-measurab
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.